Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Tafenoquine in Healthy Adults
NCT07373743Phase 1Not yet recruiting
- Sponsor
- Upstate Medical University
- Start
- May 2026
- Primary completion
- Mar 2027
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tafenoquine in malaria (4 arms), sponsored by Upstate Medical University. Primary endpoints: Tafenoquine levels in blood over time at Day 57 and Tafenoquine levels in urine over time at Day 57. Planned start May 2026; status: not yet recruiting.
02
Drugs
tafenoquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT07373743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07373743.